NanoViricides IncNYSE American:NNVC
- LAST PRICE1.4450
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3500/ 13
- Ask / Lots1.4800/ 90
- Open / Previous Close0.0000 / 1.4450
- Day Range---
- 52 Week Range
- Volume1
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | NNVC |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NanoViricides Inc | 16.8M | -2.4x | --- |
Bio Path Holdings Inc | 16.7M | -1.1x | --- |
Bellerophon Therapeutics Inc | 16.5M | -0.9x | --- |
Galmed Pharmaceuticals Ltd | 17.1M | -0.8x | --- |
Raphael Pharmaceutical Inc | 17.2M | -5.4x | --- |
Theriva Biologics Inc | 17.3M | -0.8x | --- |
Company Information
NanoViricides, Inc. is a nano-biopharmaceutical company. The Company is engaged in discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company's nanoviricide technology enables direct attacks at multiple points on a virus particle. The nanomedicines technology also enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company is developing antiviral drug candidate, NV-CoV-2 drug for the treatment of COVID-19 infected sick persons. Its other clinical drug candidate NV-HHV-101 a skin cream for the treatment of shingles rash. The Company also offers several additional pre-clinical drug development programs, including Herpes Simplex Viruses (HSV-1 that causes cold sores, and HSV-2 that causes genital ulcers), HIV/AIDS, Influenza, Dengue viruses, and Ebola/Marburg.
Contact Information
- Headquarters
- 1 Controls DriveSHELTON, CT, United States 06484
- Phone
- 203-937-6137
- Fax
- 203-859-5095
Executives
- Chairman of the Board, President
- Anil Diwan
- Chief Financial Officer
- Meeta Vyas
- Independent Director
- Makarand Jawadekar
- Independent Director
- Theodore Rokita
- Independent Director
- Brian Zucker
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 11.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.13 |
EPS | $-0.61 |
Book Value | $1.99 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
